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Abstract
Background: Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials
(INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by
reducing the decline in the forced vital capacity (FVC). Although the INPULSIS™ trials indicate that nintedanib may
serve to prevent acute exacerbations or delay the time to the first acute exacerbation, a certain number of IPF patients
develop acute exacerbations while receiving nintedanib. However, there has been no report on the readministration of
nintedanib in IPF patients who develop acute exacerbations during initial treatment with nintedanib.
Case Presentation: A 64-year-old man with IPF had nintedanib added to his ongoing pirfenidone therapy. He
developed dyspnea after 65 days and presented with hypoxemia after 68 days. At presentation, chest computed
tomography showed newly developed diffuse ground glass opacities with the pre-existing subpleural reticular
shadows. Because of the absence of infection or other potential causative factors, we diagnosed an acute exacerbation
of IPF. Nintedanib was temporarily discontinued and the acute exacerbation was successfully managed with intensive
treatment. We re-initiated nintedanib 30 days after cessation, which helped stabilize his FVC for 8 months. Nintedanib
was safely continued for 28 months until he died of a bacterial infection.
Conclusion: To the best of our our knowledge, this is the first reported case of an acute exacerbation of IPF during
nintedanib treatment, wherein nintedanib was safely and successfully restarted after treatment of the acute
exacerbation. Our case indicates that nintedanib can be safely resumed and a desired effect on FVC can be obtained,
even in IPF patients who develop acute exacerbations. However, we recommend close monitoring and appropriate
measures until the long-term safety profile is clarified.
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Background
Nintedanib is a multi-target receptor tyrosine kinase in-
hibitor that inhibits vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), and
fibroblast growth factor (FGF) [1]. In patients with idio-
pathic pulmonary fibrosis (IPF), two replicate random-
ized phase 3 trials, INPULSIS™-1 and -2, demonstrated
that nintedanib reduced the decline in the forced vital
capacity (FVC), with a manageable side-effect profile [2].
Furthermore, the results of an earlier phase 2 trial sug-
gested that nintedanib was associated with fewer acute
exacerbations of IPF [3]. In the INPULSIS™-2 trial, there
was a significant increase in time to the first acute ex-
acerbation in the nintedanib group when compared with
that in the placebo group; however, this was not ob-
served in the INPULSIS™-1 trial. Although a prespecified
verification by a central adjudication committee showed
that the risk of acute exacerbation of IPF was signifi-
cantly lower in the nintedanib group than in the placebo
group [4], a certain number of IPF patients developed
acute exacerbation in the nintedanib group. However,
there have been no reports on the readministration of
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nintedanib in patients who developed acute exacerbation
during initial treatment with nintedanib.
Case Presentation
Case report
We present the case of a 64-year-old male former
smoker with IPF. He presented to our hospital com-
plaining of dry cough in September 2005. Chest com-
puted tomography (CT) at that time revealed subpleural
reticular shadow predominantly in the lower lobes, with-
out apparent honeycombing (Fig. 1a, b). Surgical lung
biopsy showed patchy distribution of dense fibrosis, fi-
broblastic foci, and normal lung with microscopic hon-
eycombing (Fig. 1c, d). Thus, the diagnosis of IPF was
confirmed. Although pirfenidone was administered as
the first-line treatment, his FVC gradually decreased.
Therefore, in October 2010, we added nintedanib to the
ongoing pirfenidone therapy. Nintedanib was adminis-
tered at a dose of 50 mg twice daily for 28 days as part
of a phase 2 dose escalation trial [5].
From October 2011, nintedanib was initiated and
continuously administered at a dose of 150 mg twice
daily. He developed dyspnea 65 days after initiating the
treatment dose of 150 mg twice daily and presented to
our hospital on day 68. Chest CT showed newly devel-
oped diffuse ground glass opacities (Fig. 2). He had
hypoxemia with a resting partial pressure of oxygen in
arterial blood of 53.6 torr on room air. Laboratory in-
vestigation revealed high serum levels of Krebs von den
Lungen-6 (1114 U/mL), surfactant protein D (269.5 ng/
mL), and lactate dehydrogenase (258 IU/L). The possi-
bility of infection was eliminated based on the results
of sputum and blood culture, serum β-D glucan, and
cytomegalovirus antigen testing. The possibilities of
left-sided heart failure and pulmonary embolism were
also ruled out, thus we diagnosed an acute exacerba-
tion of IPF. In accordance with the study protocol, nin-
tedanib was immediately discontinued and intensive
treatment comprising methyl prednisolone pulse ther-
apy, direct hemoperfusion using a polymyxin B immo-
bilized fiber column, intravenous cyclophosphamide,
and cyclosporine was initiated. Subsequently, his clin-
ical symptoms, PaO2/FiO2 ratio, and imaging findings
gradually improved.
Under careful observation, nintedanib was readminis-
tered at a dose of 150 mg twice daily, 30 days after it
had been stopped. Although his FVC temporarily de-
creased after the acute exacerbation, it remained stable
from May 2012 to January 2013 (2.11 L to 2.10 L)
(Fig. 3). Nintedanib was safely continued without the re-
currence of acute exacerbations until he died of a bacter-
ial infection in February 2014.
Fig. 1 Representative photographs from radiographic and microscopic examination before starting nintedanib. Chest X-ray (a) and chest high
resolution computed tomography (b) before starting nintedanib revealed subpleural reticular shadowing that was predominantly in the lower lobes,
without honeycombing. Pathological examination of a surgical lung biopsy specimen showed subpleural fibrosis and microscopic honeycombing
(c; hematoxylin and eosin stain, low-power field) with patchy distribution of dense fibrosis, fibroblastic foci (*), and normal lung (d; hematoxylin and
eosin stain, high-power field). Thus, the diagnosis of idiopathic pulmonary fibrosis was confirmed
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Discussion
To the best of our knowledge, this is the first reported
case of nintedanib being successfully and safely readmi-
nistered for IPF after being stopped because of an acute
exacerbation during initial treatment. Although it re-
mains to be determined whether nintedanib can induce
acute exacerbation of IPF, we temporarily discontinued
the treatment because of this possibility and were able to
resume nintedanib without the recurrence of acute
exacerbation. The clinical course of the present case in-
dicates that nintedanib itself does not induce acute ex-
acerbation of IPF.
Some previous reports support the supposition that
nintedanib may not induce acute exacerbation of IPF.
First, although it is unknown whether the inhibition of
PDGF and FGF receptors can induce exacerbation of
interstitial lung disease, studies have indicated that beva-
cizumab, a recombinant humanized monoclonal anti-
body against VEGF, does not increase the risk of such
exacerbations [6, 7]. Second, in the phase 3 LUME-Lung
trials, which assessed the efficacy and safety of nintedanib
in addition to docetaxel (LUME-Lung-1) [8] or peme-
trexed (LUME-Lung-2) [9] as the second-line therapy for
non-small-cell lung cancer, the occurrence of drug-
induced interstitial lung disease did not differ between the
nintedanib and placebo groups (LUME-Lung-1: 1.4 and
0.8 %, respectively; LUME-Lung-2: 0.6 and 0.8 %, respect-
ively). Although these are only the preliminary results of
ongoing clinical studies, they indicate that nintedanib it-
self does not cause interstitial lung disease.
Acute exacerbations of IPF are generally severe and life
threatening, with a reported median survival of only
Fig. 2 Chest X-ray and high resolution computed tomography at
acute exacerbation of idiopathic pulmonary fibrosis onset. Chest X-ray
(a) and high resolution computed tomography (b) at the onset of
acute exacerbation. On day 68, chest high resolution computed
tomography showed newly developed, diffuse, ground glass opacities
Fig. 3 Chronological change in forced vital capacity before and after acute exacerbation of idiopathic pulmonary fibrosis. Under careful observation,
nintedanib was restarted 30 days after cessation. Although the forced vital capacity was temporally decreased after the acute exacerbation, it remained
stable from May 2012 to January 2013. Abbreviations; PMX-DHP, direct hemoperfusion using a polymyxin B immobilized fiber column
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2.2 months after their onset [10]. To date, it remains un-
clear whether nintedanib offers the desired beneficial ef-
fect in such patients. However, in the present case, there
was an apparent inhibitory effect on FVC reduction over
an 8-month period after the readministration of ninteda-
nib. A report on the interim analysis of nintedanib in an
open-label extension of the INPULSIS™ trials (INPUL-
SIS™-ON) [11] revealed that it provided a positive effect
on slowing disease progression for 2 years. Together
with the results of the present case, we believe that it is
reasonable to assume that the readministration of ninte-
danib may slow disease progression, even in patients
with IPF and a history of acute exacerbation during
therapy.
Conclusions
Our case indicates that nintedanib can be safely resumed
and expected to achieve the desirable clinical effect on
FVC in patients with IPF who develop acute exacerba-
tion during treatment. However, close monitoring will
be needed until its long-term safety profile is elucidated.
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